Skip to main content
Unchecking box will stop auto data updates
Delayed Price USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 0.15
Day High 0.22
Open:0.22
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
N/A

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
GlobeNewswire - Thu Apr 19, 6:01AM CDT
GlobeNewswire - CMTX
Thu Apr 19, 6:01AM CDT
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018. Management will host a conference call to review the results at 4:30 p.m. ET on the same day.
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU(TM)
GlobeNewswire - Thu Apr 12, 6:00AM CDT
GlobeNewswire - CMTX
Thu Apr 12, 6:00AM CDT
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering DEXYCU(TM), the Company's FDA-approved long-acting intraocular product for the treatment of postoperative inflammation.
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc.
GlobeNewswire - Wed Mar 28, 3:05PM CDT
GlobeNewswire - CMTX
Wed Mar 28, 3:05PM CDT
Acquisition and additional funding significantly accelerate the company's
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.15 unch no change
on 01/12/16
Period Open:0.35
Price movement based on the high, low and last over the given period.
0.39 -61.54% decrease
on 12/24/15
-0.20 (-57.14%) decrease
since 12/11/15
3-Month 0.15 unch no change
on 01/12/16
Period Open:0.90
Price movement based on the high, low and last over the given period.
1.05 -85.71% decrease
on 10/15/15
-0.75 (-83.33%) decrease
since 10/12/15
52-Week 0.15 unch no change
on 01/12/16
Period Open:5.73
Price movement based on the high, low and last over the given period.
8.03 -98.13% decrease
on 04/15/15
-5.58 (-97.38%) decrease
since 01/12/15

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement